- :: AccuMax Array, Tissue Micro Array ::

Request sample/catalog CATALOG


		Home > Products > Products List

       Customer comments

         "I would like to try test slides A712 and A718. I already placed the order yesterday for 8 different arrays,
          some were in duplicates. I liked my previous results with your lung and multi-tissue Ca arrays. The quality
          was very good. I can tell this based on my extensive experience with other companies. You do an
         excellent job." - Svetlana Pack, Ph.D. LIP/NIAID/NIH

         "In comparison to the arrays we have produced ourselves or received from collaborators, the ones we got
         from ISU ABXIS were of superior quality. Before a lot of tissue cores detached during the processing or
         the morphology was compromised. Not so with the one we received from you. It had outstanding tissue
         morphology and the information on each sample found on the accompanying CD was exceeding my
         expectations. In addition, it is helpful for analysis to have more than one core of each sample. After
        sectioning a few slides from our in-house arrays most tissues were not available due to different core
        thickness, so yours provides much better consistency and we have already ordered more of the esophageal
        array we tested. Thank you for providing such outstanding service." - Claudia Andl, Ph.D. from University of
         Pennsylvania.

        "I wanted to let you know that we have used the various tissue arrays and were very much impressed
         by the quality of tissue preparation and preservation. We are having an outside pathologist look also
         at the staining in more detail to evaluate tissue quality but it looks really great. We will proceed with
         some candidate antibody and we are definitely interested in further your services and business as we
         are developing new target and antibody in the near future. Thank you very much."- Pharmaceutical company

         "I found the TMAs to be well preserved, good morphology, good variety of tumor types, adequate tissues
          in each sample, and they stained well for immunohistochemistry. I think such arrays would work great
          for first pass screening." - Pharmaceutical company

References

No.	Published	AccuMax Array	Journal	Paper Title	Organization
1	2004	Colon_Custom TMA	Oncogene (I)	Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas	Yonsei University
2	2004	A221_Brain	Cancer Cell	Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases	Harvard Medical School
3	2004	A301_Various Ca.	Oncogene (II)	Role of the BLT2, a leukotriene B4 receptor, in Ras transformation	Korea University
4	2005	A301_Various Ca.	Cell Death and Differentiation	Cyclin G1 overcomes radiation-induced G2 arrest and increases cell death through transcriptional activiation of cyclin B1	Korea Institute of Radiological and Medical Sciences
5	2005	A207_Pancreas	Cancer Research	Overexpressed P-Cadherin/CDH3 Promotes Motility of Pancreatic Cancer Cells by Interacting with p120ctn and Activating Rho-Family GTPases	Laboratory of Molecular Medicine, Human Genome Center, The University of Tokyo
6	2005	A202_Breast/ A207_Pancreas	Cancer Cell	CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness	Cancer Research UK
7	2005	A401_Thyroid	British Journal of Cancer	Decreased expression of haemoglobin beta(HBB) gene in anaplastic thyroid cancer recovery of its expression inhibits cell growth	Nippon Medical SchoolKanagawa Prefectural Cancer Center
8	2005	Custom TMA	Invasive Ductal Carcinoma of Breast	Immuohistochemical and Clinicopathologic Characteristics of Invasive Ductal Carcinoma of Breast with Micropapillary Carcinoma Component	Univ. of Ulsan College of Medicine, Ajou University
9	2005	Custom TMA	Oncogene	Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestina stromal tumors	Yonsei University
10	2006	A202(III)_Breast	Molecular Cancer Therapeutics	C35(C17orf37) is a novel tumor biomaker abundantly expressed in breast cancer	Vaccinex, INC.
11	2006	A302_Prostate	Cell	Macrophage/Cancer Cell interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway	Univ. of California
12	2006	A712(II)_Breast	Journal of Biological Chemistry	Lysyl Oxidase Interacts w/ Hormone Placental Lactogen and Synergistically Promotes Breast Epithelial Cell Proliferation and Migration	Cardiovascular Research Center, Univ. of Hawaii
13	2006	A215_Urinary	Clinical Cancer Research	Molecular Profiling of ADAM12 in human Bladder Cancer	Institute of Molecular Pathology, Univ. of Copenhagen
14	2006	Prostate	Clinical Cancer Research	Expression of Novel Molecules, MICAL2-PV (MICAL2 Prostate Cancer Variants), Increas with High Gleason Score and Prostate Cancer Progression	Human Genome Center, Tokyo University
15	2006	A206_Lung	Respiratory Research	WFDC2(HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung	University of Sheffield
16	2006	A218_Esophagus Ca.	Cancer Research	Coordinated Functions of E-Cadherin and Transforming Growth Factor β Receptor II in vitro and In Vivo	Abramson Cancer Center
17	2006	A207_Pancreas	Japanese Cancer Association	EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth	Human Genome Center, Tokyo University
18	2007	A218_Esophagus Ca.	The American Journal of Pathology	Dysregulation of Caludin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells	The Wistar Institute, Univ. of Pennsylvania
19	2007		Molecular Cancer Therapeutics	The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocrcinoma tumor xenografts in vivo	Raven Biotechnologies Inc.
20	2007	A207_Pancreas	Cancer Research	Intersex-like (IXL) is a Cell Survival Regulator n Pancreatic Cancer with 19q13 Amplification	Laboratory of Cancer Genetics
21	2007	A207(III)_Pancreas	Carcinogenesis Advance Access	WNT5A - target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer	University of Ulm
22	2007	A202_Breast	Cell Biology	CXCR7(RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature	ChemoCentryx, Inc

Catalog no.	Description	Cases	Spots			Diameter	Price	Package (5 slides)
			Total	Cancer	Normal
A103(VI)	Normal tissues, more than single spot(Duplicate)	45	90	0	90	1	160	720

Catalog no.	Description	Cases	Spots			Diameter	Price	Package (5 slides)
			Total	Cancer	Normal
A201(IV)	Various cancer tissues(Duplicate)	44	88	88	0	1	150	675

Catalog no.	Description	Cases	Spots			Diameter	Price	Package (5 slides)
Catalog no.	Description	Cases	Total	Cancer	Normal	Diameter	Price	Package (5 slides)
A202(V)	Breast cancer tissues(Duplicate)	45	98	90	8	1	150	675
A203(I)	Colon cancer tissues(Duplicate)	50	104	100	4	1	160	720
A203(II)	Colon cancer tissues- liver metastasis	18	90	72	18	1	160	720
A203(III)	Colon cancer tissues-liver metastasis	18	90	72	18	1	160	720
A203(IV)	Colon cancer tissues-liver metastasis	14	70	56	14	1.5	150	675
A203(V)	Colon cancer tissues(Duplicate)	45	98	90	8	1	150	675
A203(VI)	Colon cancer tissues(Duplicate)	45	98	90	8	1	150	675
A204	Liver cancer tissues-Hepatocellular carcinoma(Duplicate)	35	74	70	4	1	140	630
A204(II)	Liver cancer tissues-Hepatocellular carcinoma(Duplicate)	35	78	70	8	1	140	630
A205	Liver cancer tissues- Cholangiocarcinoma tissues(Duplicate)	46	96	92	4	1	140	630
A206	Lung cancer tissues(Duplicate)	40	84	80	4	1	150	675
A206(IV)	Lung cancer tissues(Duplicate)	45	98	90	8	1	150	675
A207(II)	Pancreas cancer tissues(Duplicate)	30	64	60	4	1	160	720
A207(IV)	Pancreas cancer tissues(Duplicate)	33	74	66	8	1	160	720
A207(V)	Pancreas cancer tissues(Duplicate)	30	68	60	8	1	160	720
A209	Stomach cancer tissues(Duplicate)	50	104	100	4	1	140	630
A209(II)	Stomach cancer tissues(Duplicate)	40	88	80	8	1	140	630
A210	Thyroid cancer tissues(Duplicate)	33	70	66	4	1	140	630
A212	Uterus cancer tissues(Duplicate)	48	100	88	12	1	140	630
A213	Ovary cancer tissues(Duplicate)	45	94	90	4	1	140	630
A213(II)	Ovary cancer tissues(Duplicate)	43	94	86	8	1	140	630
A214	Kidney(28 cases) and ureter(3 cases) cancer tissues	31	68	62	6	1	140	630
A215	Urinary bladder cancer tissues(Duplicate)	45	94	90	4	1	140	630
A215(II)	Urinary bladder cancer tissues(Duplicate)	40	84	80	4	1	140	630
A216	Skin cancer tissues(Duplicate)	50	104	100	4	1	140	630
A217	Hepatocellular carcinoma with B-viral history(Duplicate)	50	104	100	4	1	140	630
A218(I)	Esophagus cancer tissues(Duplicate)	40	84	80	4	1	140	630
A218(II)	Esophagus cancer tissues	30	200	127	73	0.6	150	675
A218(III)	Esophagus cancer tissues(Duplicate)	40	88	80	8	1	140	630
A219	Head and neck cancer tissues(Duplicate)	45	94	90	4	1	150	675
A219(II)